Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
54.15
+0.45 (0.84%)
Jul 17, 2026, 5:35 PM CET
BME:ROVI Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 97.39 | 97.98 | 27.19 | 25.32 | 124.95 | 99.04 |
Short-Term Investments | - | - | 0.23 | - | - | - |
Cash & Short-Term Investments | 97.39 | 97.98 | 27.41 | 25.32 | 124.95 | 99.04 |
Cash Growth | 232.32% | 257.41% | 8.26% | -79.73% | 26.16% | 86.29% |
Accounts Receivable | 164.27 | 177.57 | 129.47 | 143.31 | 180.01 | - |
Inventory | 274.18 | 287.98 | 329.95 | 337.97 | 311.94 | 245.47 |
Other Current Assets | 3.44 | 3.19 | 2.69 | 2.73 | 2.03 | 1.79 |
Total Current Assets | 539.28 | 566.71 | 489.61 | 509.33 | 623.07 | 506.36 |
Net Property, Plant & Equipment | 329.26 | 330.74 | 286.62 | 253.65 | 215.54 | 181.78 |
Other Intangible Assets | 32.42 | 69.07 | 33.95 | 33.9 | 35.74 | 38.56 |
Goodwill | 2.7 | 2.7 | - | - | - | - |
Long-Term Investments | 19.2 | 19.16 | 19.52 | 0.59 | 2.2 | 1.99 |
Other Long-Term Assets | - | 3.2 | 2.33 | 2.41 | 2.14 | 3.92 |
Total Assets | 926.32 | 955.69 | 832.02 | 799.88 | 878.7 | 732.68 |
Accounts Payable | 75.76 | 204.81 | 125.33 | 141.9 | 165.78 | 97.41 |
Accrued Expenses | 7.37 | 4.4 | 2.38 | 5.26 | - | 0.68 |
Current Portion of Long-Term Debt | 27.77 | 20.41 | 23.69 | 13.19 | 12.73 | 0.71 |
Unearned Revenue | 36.64 | - | 5.25 | 39.51 | 115.39 | - |
Other Current Liabilities | - | 74.57 | - | - | - | 91.59 |
Total Current Liabilities | 147.53 | 181.22 | 156.65 | 199.84 | 293.89 | 190.39 |
Long-Term Debt | 86.67 | - | 90.72 | 52.24 | 59.44 | - |
Other Long-Term Liabilities | 5.39 | 5.81 | 3.11 | 4.31 | 4 | 4.57 |
Total Long-Term Liabilities | 92.05 | 5.81 | 93.83 | 56.55 | 63.44 | 4.57 |
Total Liabilities | 239.58 | 187.03 | 250.48 | 256.39 | 357.32 | 194.96 |
Common Stock | 3.07 | 6.15 | 3.07 | 3.24 | 3.24 | 3.36 |
Treasury Stock | -6.75 | -5.17 | -5.55 | -107.68 | -27.56 | -66.12 |
Additional Paid-in Capital | 87.64 | 87.64 | 87.64 | 87.64 | 87.64 | 87.64 |
Accumulated Other Comprehensive Income | -0.04 | -0.16 | -0.02 | -0.02 | -0.01 | -0.01 |
Retained Earnings | 589.99 | 578.93 | 486.89 | 556.21 | 456.7 | 446.1 |
Total Common Shareholders' Equity | 673.91 | 664.42 | 572.03 | 539.39 | 520.01 | 470.98 |
Minority Interest | 12.83 | 11.04 | 9.51 | 4.11 | 1.37 | - |
Shareholders' Equity | 686.73 | 675.46 | 581.54 | 543.49 | 521.38 | 470.98 |
Total Liabilities & Equity | 926.32 | 955.69 | 832.02 | 799.88 | 878.7 | 732.68 |
Total Debt | 114.44 | 20.41 | 114.41 | 65.43 | 72.17 | 0.71 |
Net Cash (Debt) | -17.05 | 77.57 | -87 | -40.11 | 52.78 | 98.32 |
Net Cash Growth | - | - | - | - | -46.32% | - |
Net Cash Per Share | -0.33 | 1.52 | -1.70 | -0.75 | 0.99 | 1.77 |
Book Value | 673.91 | 664.42 | 572.03 | 539.39 | 520.01 | 470.98 |
Book Value Per Share | 13.18 | 12.99 | 11.17 | 10.14 | 9.73 | 8.50 |
Tangible Book Value | 638.79 | 592.65 | 538.08 | 505.49 | 484.27 | 432.42 |
Tangible Book Value Per Share | 12.49 | 11.59 | 10.51 | 9.50 | 9.06 | 7.80 |